Predict your next investment

Blackthorn Therapeutics company logo
HEALTHCARE | Drug Development
blackthornrx.com

See what CB Insights has to offer

Founded Year

2016

Stage

Series B | Alive

Total Raised

$130M

Last Raised

$76M | 2 yrs ago

About Blackthorn Therapeutics

BlackThorn Therapeutics is a clinical-stage neurobehavioral health company developing artificial intelligence technologies to advance its pipeline of targeted therapeutics for treating brain disorders. The company has engineered PathFinder, a cloud-based computational psychiatry and data platform, to enable the collection, integration and analysis of multimodal data at great speed and scale. BlackThorn applies its data-driven approaches to create an understanding of the core underlying pathophysiology of neurobehavioral disorders and uses these insights to generate objective neuromarkers, which support drug target identification, patient stratification and objective clinical trial endpoints. By identifying more homogenous patient subgroups who share underlying neurobiology, BlackThorn aims to direct its drug candidates to neurobiologically-defined patient populations most likely to respond.

Blackthorn Therapeutics Headquarter Location

780 Brannan Street

San Francisco, California, 94103,

United States

415-565-7103

Latest Blackthorn Therapeutics News

Autism develops differently in girls than boys, new research suggests

Apr 16, 2021

University of Virginia Health System Credit: Dan Addison | UVA Communications New research has shed light on how autism-spectrum disorder (ASD) manifests in the brains of girls, prompting the scientists to warn that conclusions drawn from studies conducted primarily in boys should not be assumed to hold true for girls. The researchers discovered that there is a significant difference in the genes and "genetic burden" that underpin the condition in girls and boys. They also identified specific ways the brains of girls with ASD respond differently to social cues such as facial expressions and gestures than do those of girls without ASD. "This new study provides us with a roadmap for understanding how to better match current and future evidenced-based interventions to underlying brain and genetic profiles, so that we can get the right treatment to the right individual," said lead investigator Kevin Pelphrey, PhD, a top autism expert at the University of Virginia School of Medicine and UVA's Brain Institute. "This advances our understanding of autism broadly by revealing that there may well be different causes for boys vs. girls; this helps us understanding the heterogeneity within and across genders." Understanding Autism-Spectrum Disorder The new insights come from a sweeping research project, led by Pelphrey at UVA, that brings together expertise from Yale; Harvard; University of California, Los Angeles; Children's National; University of Colorado, Denver; and Seattle Children's. At UVA, key players included both Pelphrey, of the School of Medicine's Department of Neurology and the Curry School of Education and Human Development, and John D. Van Horn, PhD, of the School of Data Science and UVA's Department of Psychology. The research combined cutting-edge brain imaging with genetic research to better understand ASD's effects in girls. Those effects have remained poorly explored because the condition is four times more common in boys. Pelphrey and colleagues used functional magnetic-resonance imaging (fMRI) to examine brain activity during social interactions. They found that autistic girls used different sections of their brains than girls who did not have ASD. And, most surprisingly, the difference between girls with and without autism was not the same as the difference in the brain seen when comparing boys with and without autism, revealing different brain mechanisms at play in autism depending on a person's gender. Likewise, the underlying genetic contributors were quite different, the researchers found. Girls had much larger numbers of rare variants of genes active during the early development of a brain region known as the striatum. This suggests that the effects on the striatum may contribute to ASD risk in girls. (Scientists believe a section of the striatum called the putamen is involved in interpreting both social interaction and language.) "The convergence of the brain imaging and genetic data provides us with an important new insight into the causes of autism in girls," Pelphrey said. "We hope that by working with our colleagues in UVA's Supporting Transformative Autism Research (STAR), we will be able to leverage our findings to generate new treatment strategies tailored to autistic girls." ### Findings Published The researchers have published their findings in the scientific journal Brain. The research team consisted of Allison Jack, Catherine A.W. Sullivan, Elizabeth Aylward, Susan Y. Bookheimer, Mirella Dapretto, Nadine Gaab, John D. Van Horn, Jeffrey Eilbott, Zachary Jacokes, Carinna M. Torgerson, Raphael A. Bernier, Daniel H. Geschwind, James C. McPartland, Charles A. Nelson, Sara J. Webb, Kevin A. Pelphrey, Abha R. Gupta and the GENDAAR Consortium. Jack, the study's first author, is a faculty member at George Mason and a former graduate student at UVA. McPartland does consulting work for Blackthorn Therapeutics and has received research funding from Janssen Research and Development; he receives royalties from Guilford Press, Lambert and Springer. The research was supported by a National Institute of Mental Health (NIMH) Autism Center of Excellence Network Award (R01 MH100028), a grant from the Simons Foundation/SFARI (No. 95489) and an NIMH Institutional Research Training Grant (T32 MH018268). To keep up with the latest medical research news from UVA, subscribe to the Making of Medicine blog at http://makingofmedicine.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Blackthorn Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Blackthorn Therapeutics is included in 6 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

A

Artificial Intelligence ( AI ) in Healthcare

826 items

These healthcare startups are using AI to discover new drugs, remotely monitor patients, securely transfer patient data, and more.

G

Google In Healthcare

61 items

The healthcare companies and initiatives that Google has invested in or is a part of

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

A

Artificial Intelligence

7,362 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Blackthorn Therapeutics Patents

Blackthorn Therapeutics has filed 11 patents.

The 3 most popular patent topics include:

  • Psychiatric diagnosis
  • Genetics
  • Neuroimaging
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/23/2019

8/31/2021

Machine learning, Artificial neural networks, Psychiatric diagnosis, Classification algorithms, Artificial intelligence

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/23/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/31/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Machine learning, Artificial neural networks, Psychiatric diagnosis, Classification algorithms, Artificial intelligence

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Blackthorn Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Blackthorn Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.